Welcome to EMJ 5.2! Our latest edition of EMJ highlights the experiences of patients with rare diseases, and the clinicians and organisations working to improve their care, alongside our hot-topic scientific and clinical research insights from authors around the world. EMJ 5.2 features an independent review of the European Conference on Rare Diseases and Orphan Products (ECRD), where organisers displayed their resilience, adaptability, and innovation by delivering a fantastic programme in a new virtual format.
EMJ 5.2 2020
Latest articlesAll articles
Oral Corticosteroids for Patients with Eosinophilic Diseases: An Expert Panel View on Use, Overuse, and Strategies to Reduce Use
Severe asthma (SA), chronic rhinosinusitis with nasal polyps (CRSwNP), and eosinophilic granulomatosis with polyangiitis (EGPA) are three conditions driven by IL-5 and eosinophilic inflammation. As these conditions have high use of healthcare services, as well as lifestyle and psychological burdens, well-tolerated treatment to achieve optimal control is key.
Ocedurenone: A Novel Therapy for Uncontrolled Hypertension in Advanced Chronic Kidney Disease
Setting the scene, Bakris defined CKD as a reduction in kidney function (estimated glomerular filtration rate [eGFR] <60 mL/min/1.73 m2), alongside the presence of albuminuria (≥30 mg/day) as an indication of kidney damage.
Heated Tobacco Products and Chronic Obstructive Pulmonary Disease: A Narrative Review of Peer-Reviewed Publications
An estimated 65 million people worldwide have moderate or severe chronic obstructive pulmonary disease (COPD), an umbrella term used to describe a group of progressive lung diseases that obstruct airflow such as emphysema and chronic bronchitis. Smoking contributes to an estimated 90% of COPD cases, as the harmful chemicals produced during tobacco combustion damage the lungs and airways. Although smoking cessation is the only intervention shown to improve COPD prognosis in smokers, many patients who try to quit continue to smoke.